News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 27, 2021Clinical Stage Cellular Therapy Company Advances Product Pipeline into Kidney Failure Market
(OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney...
-
Jan 21, 2021Company Aims to Initiate Multiple Clinical Trials Following Filing of First ImmCelz® "Regenerative Immunotherapy" IND
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory Board. Dr. Reznik is a veteran of multiple startups...
-
Jan 20, 2021Breakthrough Gains for Patients in San Antonio, TX - Now Available in Austin, TX
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Urology, Neurology and Orthopedics, today announced...
-
Jan 19, 2021Possibility of Concurrent Immunological Protection with Beta Cell Regeneration Disclosed in Filed Patent Application
(OTC: CELZ) Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes. In a...
-
Jan 12, 2021Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Cell Therapy
(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to...
-
Jan 6, 2021Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell
Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical...
-
Dec 31, 2020Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart attack. Patent application #63/132472, entitled...
-
Dec 29, 2020Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon...
-
Dec 22, 2020Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifying one of the primary mechanisms of action of its ImmCelz® product in the treatment of stroke. The Company...
-
Dec 16, 2020Company Plans to Leverage Existing AmnioStem® Expertise for Novel Approach to Protecting and Regenerating Injured Brains
Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz® cell based immunotherapy for treatment of stroke. In...